Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
TELA Bio ( (TELA) ) has provided an update.
On April 29, 2026, TELA Bio announced a major reshaping of its board, with Chairman Doug Evans opting not to stand for re-election and to retire from the board after the 2026 Annual Meeting, alongside the post-meeting resignations of directors Kurt Azarbarzin, Vince Burgess, and Federica O’Brien, none of which were due to disagreements with the company. The board has nominated MiMedx CEO and veteran MedTech executive Joseph Capper—who will not be an independent director—to become chairman following his expected election at the June 9, 2026 meeting, and has appointed seasoned healthcare and life sciences figures Guido Neels, Guy Nohra, and Paul Thomas as independent Class II and III directors, each slated to receive standardized equity and cash compensation, signaling a strategic infusion of deep industry, operational, and investment expertise into TELA Bio’s governance structure.
The most recent analyst rating on (TELA) stock is a Buy with a $2.00 price target. To see the full list of analyst forecasts on TELA Bio stock, see the TELA Stock Forecast page.
Spark’s Take on TELA Stock
According to Spark, TipRanks’ AI Analyst, TELA is a Neutral.
The score is held down primarily by weak financial performance—ongoing losses, negative free cash flow, and sharply higher leverage—while technicals show only a modest short-term bounce within a longer-term downtrend. Earnings commentary is somewhat supportive due to commercial progress, but the more conservative 2026 outlook and execution risks, plus the Nasdaq bid-price deficiency, cap the overall rating.
To see Spark’s full report on TELA stock, click here.
More about TELA Bio
TELA Bio operates in the medical technology and life sciences sector, focusing on surgical reconstruction solutions that leverage biologic and synthetic materials for soft-tissue repair. The company targets hospitals, surgeons, and healthcare systems seeking advanced alternatives to traditional meshes in hernia repair and plastic and reconstructive procedures.
Average Trading Volume: 223,224
Technical Sentiment Signal: Sell
Current Market Cap: $38.48M
Find detailed analytics on TELA stock on TipRanks’ Stock Analysis page.